My position, though a slightly uncomfortable one at times like this, is set as well.
I agree on the ponatinib trial design-sure would allow for an early T315I approval, which I believe is reasonably likely, without disrupting the rest of the trial, the results of which could ultimately have positive implications for 534's viability in 1st and 2nd line indications.
Do you agree with a few of us that a positive rida/endo result could really light a fire here? What's your latest thinkng on the odds of this?
This has really been a difficult and disappointing last couple of weeks in biotech and ariad-though I knew this end of the quarter/news vacuum scenario was a real possibility, I had hoped for more.
In any event, please advise concerning the above,thanks for your response, and please check in from time to time on the "substantive" topics du jour.
Best,
bw